		TATTI DOOKET NO		CEDIAL NO			
PTO-1449		ATTY. DOCKET NO. SERVIER 403 DIV		SERIAL NO. 10/813,347			
LIST OF PRIOR ART CITED BY APPLICANT				10.010,211			
SHEET	1 OF 3		_				
	OIPE	APPLICANT G. LAVIELLE, O. MUI	LLER, M. M	ILLAN, and A. GC	BERT		
	MAR 2 4 2005	FILING DATE March 30, 2004		GROUP 1625			
	- The state of	U.S. PATENT DOC	TIMENTS				
Examiner	TRADENT!	DATE DATE	NAME	CLASS	SUB-	FILING	DATE IF
Initial	NUMBER	DAIL	TOTAL	00.00	CLASS	APPROP	
					 		
					<u> </u>		
	T T DOCUMENT T	FOREIGN PATENT D	COUNTRY	S I CLASS	SUB-	TRANSLAT	TION
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	INANSLAI	HON
						YES	NO
							
	}					1	
		OTHER PRIOF	RART				
2 1	BERENDSEN, et al.	., Psychopharmacology, 1		7-61.			
Sut			•				
1	MILLAN, et al., Euro	pean Journal of Pharmac	ology, 1997	, 325, 9-12.			
		•	- -				
	O'NEILL, et al., Pha	rmacology, Biochemistry,	and Behavi	or, 1999 , <i>63</i> , 237-	243.		
	REAVILL, et al., Brit	tish Journal of Psychopha	rmacology,	1999 , <i>126</i> , 572-57	' 4.		
	HERRICK-DAVIS, e	et al., Journal of Pharmaco	ology and Ex	xperimental Thera	peutics, 2	000, 295,	226-232.
	WOOD, et al., Drug	Development Research,	2001 , <i>54</i> , 88	3-94.	<u> </u>		
	PAIVA, et al., Psych	nopharmacology, 1988, 96	3, 395-399.				
-	DUGOVIC, Journal	Sleep Research, 1992, 1,	1163-1168.	•			
		europsychopharmacology					
	SHARPLEY, et al., t	Biological Psychiatry, 200	0 , <i>4</i> 7, 468-4	70.			
84	WATSON, et al., Ph	armacology, Biochemistry	y, and Beha	vior, 1991 , <i>39</i> , 60	5-612.		
EXAMIN							
2 t							
*EXAMIN	NER: Initial if reference considere ce and not considered. Include cop	d, whether or not citation is in copy of this form with next commun	onformance wit	th MPEP 609; Draw lin	e through c	tation if not in	n

.

.

PTO-1449	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347	
LIST OF PRIOR ART CITED BY APPLICANT			
SHEET 2 OF 3 OIP			
30	APPLICANT G. LAVIELLE, O. MULLER, M. MILLAN, and A. GOBERT		
MAR 2 4 2005	FILING DATE	GROUP	
THE MADENANCE OF	March 30, 2004	1625	
RADEMARK			

OTHER PRIOR ART

OTHER PRIOR ART
FOREMAN, et al., <i>Life Sciences</i> , 1989 , <i>45</i> , 1263-1270.
KLINT, et al., Psychopharmacology, 1995, 119, 291-294.
HIRSCHFELD, Journal of Clinical Psychiatry, 60 Suppl. 17:32-35, 1999.
POPOVA, et al., Neuroendocrinology, 2002, 76, 28-34.
Amesergide, LY-237733; Pharmaproject, Phase II Clinical Trial, 2005
KOSKINEN, et al., Pharmacology, Biochemistry and Behavior, 2000, 66, 729-738.
WHITE, et al., Pharmacology, Biochemistry and Behaviour, 1991, 39, 729-736.
MILLAN, et al., Journal of Pharmacology and Experimental Therapeutics, 2001, 298, 581-591.
MUNDO, et al., International Clinical Psychopharmacology, 2000, 15, 69-76.
MILLAN, et al., <i>Prog. Neurobiol.</i> , 1999 , 57, 1-164.
MILLAN, et al., <i>Prog. Neurobiol.</i> , 2002, 66, 355-474.
KALKMAN, et al., Int. J. Clin. Pharmacol. Res., 1997, 17, 75-77.
KALKMAN, et al., Naunyn Schmiedebergs. Arch. Pharmacol., 1994, 350, 225-229.
KALKMAN, et al., <i>Life Sci.</i> , 1994 , <i>54</i> , 641-644.
Ro-60-0759, Pharmaproject, Preclinical Trial, 2005
SB-243213, Pharmaproject, Phase I Clinical Trial, 2005
DATE CONSIDERED
6/7/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449 LIST OF PRIOR ART CITED BY APPLICANT	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347
SHEET 3 OF 3	APPLICANT G. LAVIELLE, O. MULLER, M. M	ILLAN, and A. GOBERT
MAR 2 4 2005 = 1	FILING DATE March 30, 2004	GROUP 1625

OTHER PRIOR ART

	OTHER FRIONAN
924	LY-053857, Pharmaproject, Phase II Clinical Trial (2005).
1	KANT, Pharmacol. Biochem. Behav., 1998, 59, 729-735.
	MENESES, et al., Behav. Brain Res., 1997, 87, 105-110.
	KANT, Pharmacol. Biochem. Behav., 1996, 53, 385-390.
	Di GIOVANNI, et al., Indian J. Exp. Biol., 2002, 40, 1344-1352.
	DE DEURWAERDERE, et al., Trends Pharmacol. Sci., 2001, 22, 502-504.
	MILLAN, et al., Neuropharmacology, 1998, 37, 953-955.
	FOX, et al., Drug News and Perspectives, 1999, 12:477-483.
	FOX, et al., Movement Disorders, 2000, 15:1064-1069.
821	SM-3163, Pharmaproject, Phase II Clinical Trial (2005).
EXAMINER	DATE CONSIDERED
24	6/7/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.